In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Videos|June 4, 2021
Efficacy, Safety of Nivolumab Plus Cabozantinib Versus Sunitinib for Patients With Advanced Renal Cell Carcinoma
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.
Advertisement
Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, on her presentation at the 2021 ASCO Annual Meeting on nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).
During the discussion, Apolo detailed some of the findings of the phase 3 trial around the efficacy and safety of nivolumab plus cabozantinib versus sunitinib for patients with aRCC.
Advertisement
Related to this article
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
5